Inovio Pharma Stock
Inovio Pharma Stock
Currently there is a rather positive sentiment for Inovio Pharma with 3 Buy predictions and 1 Sell predictions.
Based on the current price of 0.53 € the target price of 3 € shows a potential of 463.91% for Inovio Pharma which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Inovio Pharma stock. Criterium "Business model" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Evolus Inc | -0.880% | -7.848% | -16.214% | -35.039% | -8.220% | -44.729% | -46.787% |
| Heron Therapeutics Inc. | -1.530% | 6.405% | 19.806% | -69.444% | -60.036% | -70.121% | -95.572% |
| Rhythm Pharmaceuticals | -1.680% | -8.556% | -13.198% | 14.765% | -8.556% | 292.202% | 519.565% |
Comments
Inovio Pharmaceuticals (INO) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $4.00 price target on the stock, down from $6.00.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (INO) was downgraded by Wall Street Zen from "hold" to "sell".
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat